Alaunos Therapeutics, Inc. annual report, FY2014

Filing identity and reporting period

Important identity discrepancy: The supplied filing is ZIOPHARM Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2014—not an Alaunos Therapeutics, Inc. filing. The filing also provides unaudited quarterly data, including Q4 2014.

Business context

ZIOPHARM was a development-stage oncology biopharmaceutical company with no approved products and no product sales. Its focus was shifting toward Intrexon’s synthetic-biology and immuno-oncology programs, led by Ad-RTS-IL-12 plus veledimex, and toward CAR-T and related cell therapies. Palifosfamide, darinaparsin and indibulin were no longer being actively developed by ZIOPHARM; darinaparsin was licensed worldwide to Solasia.

Financial performance and liquidity

2014 revenue was collaboration/research-contract revenue, principally recognized from the Solasia arrangement; the company reported no product revenue. Gross margin is not meaningful for this development-stage business. No debt balance is identified in the presented balance sheet; liability-classified warrants had expired by year-end, leaving no warrant liability. The $11.723 million 2014 gain from changes in warrant fair value reduced reported net loss and was non-cash.

Changes and notable items

• Operating expenses fell 23% to $44.872 million, primarily as palifosfamide trials and other clinical activity were curtailed and following workforce reductions. R&D declined 24%; G&A declined 22%. Spending on synthetic-biology discovery and nonclinical work increased.
• Operating cash outflow improved by $22.859 million year over year, while year-end cash fell by $25.401 million. Financing cash inflow was $11.442 million, including $10.6 million from warrant exercises; 2013 financing included $53.9 million of public-offering proceeds.
• In February 2015, the company completed a public offering of 11.5 million shares, including the underwriters’ option. The detailed financing disclosure reports approximately $94.2 million of net proceeds; other filing passages refer to approximately $94.6 million.
• The January 2015 MD Anderson license provides for ZIOPHARM to issue $50 million of common stock (10,124,561 shares) and, for accelerated execution, a further $7.5 million in shares (1,597,602 shares). It also entails research funding of $15–$20 million annually for three years, with a first $3.75 million quarterly payment due within 60 days. These are significant post-year-end obligations and potential dilution.

Outlook, development and risks

Management estimated that year-end cash plus proceeds from the February 2015 offering would fund operations into the first quarter of 2017. This is a forward-looking estimate, not a guarantee; the filing warns that MD Anderson costs, clinical development spending and other requirements could exceed forecasts. The company expected R&D spending to rise significantly and planned a Houston operating presence.

• Management planned a Phase 1 brain-cancer study of Ad-RTS-IL-12 plus veledimex in the first half of 2015 and anticipated 2015 data from planned breast-cancer and glioblastoma studies. It expected up to five CAR-T programs to enter clinical testing in 2015 and off-the-shelf T-cell studies to begin in 2016.
• Exploratory Phase 2 results presented in 2014 included disease control in 3 of 7 evaluable breast-cancer patients (43%) and 7 of 18 evaluable melanoma patients (39%). These small, open-label studies do not establish efficacy; further development of intratumoral IL-12 in melanoma was paused amid changing standards of care and competition.
• Key risks include clinical failure or delays, serious cell-therapy and cytokine-related toxicities, regulatory uncertainty for gene and cell therapies, manufacturing and scale-up challenges, dependence on Intrexon and MD Anderson licenses, competition, patent disputes, and the need for future financing. CAR-T technologies licensed from MD Anderson had limited clinical data, generated in studies ZIOPHARM did not control.
• Palifosfamide’s Phase 3 PICASSO 3 trial had failed its primary progression-free-survival endpoint; the company was seeking an out-license. The MATISSE overall-survival data was expected to be presented in 2015. The filing reported no legal matters management considered materially adverse as of December 31, 2014.
• The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded disclosure controls and internal controls were effective at year-end.

Investor verification priorities

1. Confirm the issuer and filing: this is ZIOPHARM’s 2014 10-K, notwithstanding the Alaunos metadata, and its reporting period is the full fiscal year.
2. Reconcile the February 2015 offering’s net proceeds ($94.2 million in detailed disclosures versus approximately $94.6 million elsewhere) and confirm actual cash runway against subsequent spending.
3. Verify completion, accounting treatment and dilution from the MD Anderson license and incentive share issuances, as well as the timing and terms of the $15–$20 million annual research commitments.
4. Assess clinical-trial enrollment, regulatory clearance, safety and follow-up evidence behind the small Phase 2 results and management’s 2015–2016 milestones.
5. Review related-party governance and costs: Intrexon received $12.0 million for services in 2014, and director Randall Kirk was also Intrexon’s CEO, director and largest stockholder.